|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1700 AUD | +3.03% |
|
+9.68% | 0.00% |
| 10/07 | Neurizon Therapeutics Receives US FDA Support to Lift Clinical Hold on ALS Trial | MT |
| 03/07 | Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel | MT |
| Capitalization | 7.88Cr 5.18Cr 4.43Cr 4.12Cr 3.84Cr 7.09Cr 444.29Cr 49Cr 19Cr 208.03Cr 19Cr 19Cr 763.04Cr | P/E ratio 2023 |
-3.88x | P/E ratio 2024 | -9.42x |
|---|---|---|---|---|---|
| Enterprise value | 6.8Cr 4.47Cr 3.82Cr 3.56Cr 3.31Cr 6.12Cr 383.77Cr 43Cr 16Cr 179.69Cr 17Cr 16Cr 659.1Cr | EV / Sales 2023 |
6.39x | EV / Sales 2024 | 90.4x |
| Free-Float |
79.71% | Yield 2023 * |
-
| Yield 2024 | - |
More valuation ratios
* Estimated data
More news
More press releases
| 1 day | +3.03% | ||
| 1 week | +9.68% | ||
| Current month | +6.25% | ||
| 1 month | +3.03% | ||
| 3 months | +70.00% | ||
| 6 months | +3.03% |
| 1 week | 0.16 |  | 0.17 |
| 1 month | 0.16 | | 0.18 |
| Current year | 0.1 | | 0.18 |
| 1 year | 0.1 | | 0.24 |
| 3 years | 0.06 | | 0.54 |
| 5 years | 0.06 | | 0.54 |
| 10 years | 0.03 | | 0.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Thurn
CEO | Chief Executive Officer | - | 01/09/2023 |
Daniel O'Connell
DFI | Director of Finance/CFO | - | 22/04/2025 |
Stefan Ross
SEC | Corporate Secretary | - | 24/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Marcus Hughes
BRD | Director/Board Member | - | 09/05/2024 |
Sergio Duchini
CHM | Chairman | - | 17/05/2024 |
Michael Thurn
BRD | Director/Board Member | - | 31/05/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.03% | +9.68% | -22.73% | +86.81% | 5.34Cr | ||
| +0.30% | +1.58% | -16.38% | +145.93% | 71TCr | ||
| -0.50% | +0.57% | +4.68% | -10.57% | 38TCr | ||
| -1.31% | +1.67% | +13.02% | +26.49% | 34TCr | ||
| -3.64% | -2.74% | -55.22% | +8.36% | 31TCr | ||
| -2.36% | -1.23% | +0.78% | -21.03% | 26TCr | ||
| -3.00% | -1.93% | -3.83% | +18.13% | 24TCr | ||
| -1.66% | +1.10% | -14.76% | -4.83% | 22TCr | ||
| -0.79% | +3.00% | -34.75% | -11.10% | 21TCr | ||
| -1.70% | -1.00% | -10.75% | +19.50% | 16TCr | ||
| Average | -1.16% | +0.42% | -13.99% | +25.77% | 28.17TCr | |
| Weighted average by Cap. | -1.30% | +0.36% | -12.51% | +39.06% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 38.19L 25.11L 21.47L 20L 18.6L 34.37L 22Cr 2.4Cr 91.62L 10Cr 94.16L 92.22L 37Cr | 8L 6L 5L 4L 4L 8L 4.75Cr 52.81L 20.19L 2.22Cr 20.75L 20.32L 8.15Cr |
| Net income | -62.12L -40.83L -34.92L -32.52L -30.25L -55.89L -35Cr -3.9Cr -1.49Cr -16Cr -1.53Cr -1.5Cr -60Cr | -76.73L -50.44L -43.13L -40.18L -37.37L -69.05L -43Cr -4.81Cr -1.84Cr -20Cr -1.89Cr -1.85Cr -74Cr |
| Net Debt | -16.73L -11L -9L -9L -8L -15.05L -9.44Cr -1.05Cr -40.13L -4.42Cr -41.24L -40.39L -16Cr | -1.07Cr -70.54L -60.32L -56.18L -52.25L -96.55L -61Cr -6.73Cr -2.57Cr -28Cr -2.65Cr -2.59Cr -103.94Cr |
More financial data
* Estimated data
Employees
4
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/25/14 | 0.1700 $ | +3.03% | 4,20,595 |
| 11/25/11 | 0.1650 $ | +3.13% | 6,06,693 |
| 10/25/10 | 0.1600 $ | 0.00% | 87,230 |
| 09/25/09 | 0.1600 $ | +3.23% | 1,81,543 |
| 08/25/08 | 0.1550 $ | 0.00% | 2,06,928 |
Delayed Quote Australian S.E., July 14, 2025 at 11:05 am IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1650AUD
Average target price
0.4200AUD
Spread / Average Target
+154.55%
Annual profits - Rate of surprise
- Stock Market
- Equities
- NUZ Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition